541 related articles for article (PubMed ID: 21999341)
1. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Segreti J; Jones RN; Bertino JS
J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
[TBL] [Abstract][Full Text] [Related]
2. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
3. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
Donnenfeld ED; Comstock TL; Proksch JW
J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Harper T; Miller D; Flynn HW
Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
[TBL] [Abstract][Full Text] [Related]
5. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
6. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
Bertino JS; Zhang JZ
Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
[TBL] [Abstract][Full Text] [Related]
8. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Alfonso E
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Norcross EW; Sanders ME; Moore Q; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
J Ocul Pharmacol Ther; 2010 Jun; 26(3):237-43. PubMed ID: 20565309
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Moore QC; Norcross EW; Shafiee A; Marquart ME
J Ocul Pharmacol Ther; 2010 Apr; 26(2):193-8. PubMed ID: 20334537
[TBL] [Abstract][Full Text] [Related]
11. In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.
Haas W; Pillar CM; Hesje CK; Sanfilippo CM; Morris TW
J Antimicrob Chemother; 2011 Apr; 66(4):840-4. PubMed ID: 21393192
[TBL] [Abstract][Full Text] [Related]
12. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
Kim DH; Stark WJ; O'Brien TP; Dick JD
Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
[TBL] [Abstract][Full Text] [Related]
13. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
14. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
16. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections.
Mah FS
Curr Opin Ophthalmol; 2004 Aug; 15(4):316-20. PubMed ID: 15232471
[TBL] [Abstract][Full Text] [Related]
17. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation.
Chung JL; Lim EH; Song SW; Kim BY; Lee JH; Mah FS; Seo KY
Cornea; 2013 Jul; 32(7):1046-51. PubMed ID: 23615274
[TBL] [Abstract][Full Text] [Related]
18. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
Benitez-Del-Castillo J; Verboven Y; Stroman D; Kodjikian L
Clin Drug Investig; 2011; 31(8):543-557. PubMed ID: 21604820
[TBL] [Abstract][Full Text] [Related]
19. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
McCulley JP; Caudle D; Aronowicz JD; Shine WE
Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
[TBL] [Abstract][Full Text] [Related]
20. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans.
Costello P; Bakri SJ; Beer PM; Singh RJ; Falk NS; Peters GB; Melendez JA
Retina; 2006 Feb; 26(2):191-5. PubMed ID: 16467677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
